GlassScriptPhysician profile
Beata Pieczara
NPI 1255444394
$1,922.43
in general payments reported to CMS, 2019-2025
40 companies · $650 in 2025
The $650 reported for 2025 was more than what 83% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $132 · 2020: $14.95 · 2021: $82.54 · 2022: $143 · 2023: $470 · 2024: $429 · 2025: $650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,307 · Education: $243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,306.57 |
| Education | $242.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $271.32 | 2021-2025 | |
| Seagen INC. | $182.69 | 2023 | Padcev |
| Astrazeneca Pharmaceuticals LP | $120.41 | 2023-2025 | Lynparza |
| Janssen Biotech, INC. | $112.60 | 2023-2025 | Darzalex, Talvey, Tecvayli |
| Abbvie INC. | $110.89 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $106.24 | 2023-2025 | Opdivo |
| Incyte Corporation | $73.04 | 2025 | Jakafi |
| Merck Sharp & Dohme LLC | $67.34 | 2019-2025 | Keytruda, Lynparza |
| Astellas Pharma US INC | $56.88 | 2023-2025 | Xtandi |
| Adaptive Biotechnologies Corporation | $49.11 | 2024-2025 | Clonoseq |
| Glaxosmithkline, LLC. | $48.71 | 2023-2025 | Ojjaara |
| Celgene Corporation | $48.31 | 2023-2024 | Pomalyst, Reblozyl |
| Geron Corporation | $46.72 | 2025 | Rytelo |
| Genzyme Corporation | $44.55 | 2023-2024 | |
| Blueprint Medicines Corporation | $39.22 | 2023-2025 | Ayvakit |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beata Pieczara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.